YOUR SEARCH FOR Text 186 RESULTS
101 of Total
0000879169-24-000045 | 10-K | Incyte
… SEC Filing Details Annual Reports Quarterly Reports SEC …
102 of Total
0001628280-25-004633 | 10-K | Incyte
… SEC Filing Details Annual Reports Quarterly Reports SEC …
103 of Total
Incyte Stories from Researchers and Scientists | Incyte.com
… Moments of Clarity: Finding Relief from Atopic Dermatitis . View Story The Unseen Journey . …
104 of Total
State Disclosures | Incyte.com
… in prescription drug marketing, to provide the wholesale acquisition cost (WAC) of the … Opzelura ® (ruxolitinib) Disclosure Form Pemazyre ® (pemigatinib) Disclosure Form Zynyz ® …
105 of Total
Our Global Responsibility: By the Numbers | Incyte Stories
… September 10, 2024 Our Global Responsibility: By the Numbers At Incyte, every step we take … efforts from last year—January 1, 2023, through December 31, 2023—highlighting our use of …
106 of Total
A Day in the Life of David Burns | Incyte Stories
… December 5, 2023 A Day in the Life—David Burns …
107 of Total
0000879169-22-000010 | 10-Q | Incyte
… SEC Filing Details Annual Reports Quarterly Reports SEC …
108 of Total
0000879169-23-000016 | 10-Q | Incyte
… SEC Filing Details Annual Reports Quarterly Reports SEC …
109 of Total
0000879169-23-000025 | 10-Q | Incyte
… SEC Filing Details Annual Reports Quarterly Reports SEC …
110 of Total
0000879169-23-000041 | 10-Q | Incyte
… SEC Filing Details Annual Reports Quarterly Reports SEC …